Prednimustine (BioDeep_00000182587)
Secondary id: BioDeep_00000012896, BioDeep_00001868578
human metabolite blood metabolite
代谢物信息卡片
化学式: C35H45Cl2NO6 (645.2624)
中文名称: 泼尼莫司汀
谱图信息:
最多检出来源 Homo sapiens(blood) 6.45%
分子结构信息
SMILES: CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)COC(=O)CCCc1ccc(N(CCCl)CCCl)cc1
InChI: InChI=1S/C35H45Cl2NO6/c1-33-14-12-26(39)20-24(33)8-11-27-28-13-15-35(43,34(28,2)21-29(40)32(27)33)30(41)22-44-31(42)5-3-4-23-6-9-25(10-7-23)38(18-16-36)19-17-37/h6-7,9-10,12,14,20,27-29,32,40,43H,3-5,8,11,13,15-19,21-22H2,1-2H3
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AA - Nitrogen mustard analogues
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D009676 - Noxae > D000477 - Alkylating Agents
同义名列表
8 个代谢物同义名
[2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate; [2-(11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl] 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoate; 2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl}-2-oxoethyl 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoate; 2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethyl 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid; Prednimustine; Stereocyt; Sterecyt; Prednimustine
数据库引用编号
14 个数据库交叉引用编号
- ChEBI: CHEBI:82524
- KEGG: C19512
- PubChem: 281327
- PubChem: 34457
- HMDB: HMDB0256744
- DrugBank: DB12832
- ChEMBL: CHEMBL4752877
- ChEMBL: CHEMBL2103751
- MeSH: Prednimustine
- chemspider: 247793
- CAS: 29069-24-7
- PMhub: MS000027227
- PubChem: 124490184
- KNApSAcK: 82524
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
亚细胞结构定位 | 关联基因列表 |
---|
文献列表
- K S Wilson. Regression of follicular lymphoma with Devil's Claw: coincidence or causation?.
Current oncology (Toronto, Ont.).
2009 Aug; 16(4):67-70. doi:
10.3747/co.v16i4.401
. [PMID: 19672427] - M Filipits, U Jaeger, I Simonitsch, C Chizzali-Bonfadin, H Heinzl, R Pirker. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2000 Sep; 6(9):3417-23. doi:
NULL
. [PMID: 10999723] - S Lindgren, A Danielsson, R Olsson, H Prytz, S Eriksson. Prednimustin treatment in primary biliary cirrhosis: a preliminary study.
Journal of internal medicine.
1992 Feb; 231(2):139-41. doi:
10.1111/j.1365-2796.1992.tb00515.x
. [PMID: 1541936] - E Musch, M Malek, J Peter-Katalinic, H Egge, H Rink, B Lathan, E Riedel. Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.
Cancer chemotherapy and pharmacology.
1992; 29(4):297-304. doi:
10.1007/bf00685948
. [PMID: 1537076] - L Bastholt, C J Johansson, P Pfeiffer, L Svensson, S A Johansson, P O Gunnarsson, H Mouridsen. A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.
Cancer chemotherapy and pharmacology.
1991; 28(3):205-10. doi:
10.1007/bf00685510
. [PMID: 1855277] - U Loos, E Musch, M Malek, E Riedel. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration.
Oncology.
1991; 48(4):334-42. doi:
10.1159/000226953
. [PMID: 1891177] - M M Oppitz, E Musch, M Malek, H P Rüb, G E von Unruh, U Loos, B Mühlenbruch. Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.
Cancer chemotherapy and pharmacology.
1989; 23(4):208-12. doi:
10.1007/bf00451643
. [PMID: 2924378] - B Hartley-Asp, P O Gunnarsson, J Liljekvist. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.
Cancer chemotherapy and pharmacology.
1986; 16(2):85-90. doi:
10.1007/bf00256154
. [PMID: 3948307] - D R Newell, A H Calvert, K R Harrap, T J McElwain. Studies on the pharmacokinetics of chlorambucil and prednimustine in man.
British journal of clinical pharmacology.
1983 Feb; 15(2):253-8. doi:
10.1111/j.1365-2125.1983.tb01494.x
. [PMID: 6849759] - R C Gaver, G Deeb, K A Pittman, B F Issell, A Mittelman, R D Smyth. Disposition of orally administered 14C-prednimustine in cancer patients.
Cancer chemotherapy and pharmacology.
1983; 11(3):139-43. doi:
10.1007/bf00254192
. [PMID: 6640823] - H Ehrsson, I Wallin, S O Nilsson, B Johansson. Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).
European journal of clinical pharmacology.
1983; 24(2):251-3. doi:
10.1007/bf00613827
. [PMID: 6840176] - A Sayed, W V Hove, A Vermeulen. Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone.
Oncology.
1981; 38(6):351-5. doi:
10.1159/000225586
. [PMID: 7301281] - D R Newell, C R Shepherd, K R Harrap. The pharmacokinetics of prednimustine and chlorambucil in the rat.
Cancer chemotherapy and pharmacology.
1981; 6(1):85-91. doi:
10.1007/bf00253015
. [PMID: 7273268] - D R Newell, L I Hart, K R Harrap. Estimation of chlorambucil, phenyl acetic mustard and prednimustine in human plasma by high-performance liquid chromatography.
Journal of chromatography.
1979 Sep; 164(1):114-9. doi:
10.1016/s0378-4347(00)81580-7
. [PMID: 541393]